Carlos Solórzano, PhD is a Senior Principal at Section 32. Carlos has more than a decade of experience in healthcare spanning academic research, investment banking, corporate strategy and BD as well as venture capital prior to joining Section 32. At Section 32, Carlos focuses on the firm’s investment sourcing, diligence, and deal execution efforts primarily in healthcare.
Prior to Section 32, Carlos was a Senior Associate at Pivotal bioVenture Partners where he participated in nine investments into therapeutics companies across various stages of development and financing in various therapeutic areas. During his tenure at Pivotal, Carlos was an observer on the board or led diligence for Akouos (NASDAQ: AKUS), Avalyn, Evommune, Plexium and Arkuda.
Carlos previously was an Associate Director in the corporate strategy and business development team at Ultragenyx Pharmaceutical where he worked on competitive intelligence, as well as portfolio, commercial and BD strategy. In particular, Carlos participated in Ultragenyx’ option to acquire GeneTx (ASO for Angelman Syndrome), the expansion of Ultragenyx’ collaboration agreement with Arcturus Therapeutics (nucleic acid therapeutics including mRNA), as well as in the technology and portfolio strategy of Ultragenyx’ gene therapy platform.
Prior to Ultragenyx, Carlos worked as an equity research associate at Deutsche Bank and Oppenheimer & Co. covering smid- and large-cap biotech companies. Carlos has a BS in Chemical Engineering from Cal Poly Pomona, earned a PhD in Pharmacology from UC Irvine, and was an NIH postdoctoral scholar at UC San Francisco where he investigated the neurobiology of pain and itch.